Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Blankenship

Neurological Surgery Fayetteville, AR Medical Doctor

NPI 1245202274 CMS profile 101801

2793 E Millennium, Suite 1, Fayetteville, AR 72703

Open in the dashboard

General payments

$217,385

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$600,000

6 holdings reported · through program year 2025

Through program year 2025, James Blankenship of Fayetteville, AR is reported in the CMS Open Payments database as having received $217,385 across 78 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $600,000 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,315 10
2024 General $32 2
2023 General $34,105 9
2022 General $41,999 18
2021 General $31,038 10
2020 General $37,017 9
2019 General $32,880 20
2025 Ownership $100,000 1
2024 Ownership $100,000 1
2023 Ownership $100,000 1
2022 Ownership $100,000 1
2021 Ownership $100,000 1
2020 Ownership $100,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Blankenship
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to James Blankenship were reported at $40,315. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year James Blankenship Neurological Surgery median Middle half National median
2019 $32,880 $582 $138–$3,006 $163
2020 $37,017 $294 $76–$2,174 $114
2021 $31,038 $387 $105–$2,432 $132
2022 $41,999 $542 $139–$2,989 $149
2023 $34,105 $534 $145–$2,697 $160
2024 $32 $574 $155–$3,046 $164
2025 $40,315 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. The Institute of Musculoskeletal Science and Education $197,819 46 payments
  2. Camber Spine Technologies $19,060 22 payments
  3. Philadelphia Medical Management Company LLC $321 2 payments
  4. Shockwave Medical, Inc $80 4 payments
  5. Midsouth Orthopedics $54 1 payment
  6. Abbott Laboratories $40 2 payments
  7. Novo Nordisk Inc $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $168,388 27 payments
  2. Consulting Fee $39,785 23 payments
  3. Travel and Lodging $6,545 7 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,600 1 payment
  5. Food and Beverage $746 18 payments
  6. Current or prospective ownership or investment interest $321 2 payments
Products named General payments · program years 2019–2025
  1. Spira $55,893 9 payments
  2. Enza $43,827 8 payments
  3. Enza 2.0 $39,744 9 payments
  4. Enza A $1,800 1 payment
  5. Spira-C $800 1 payment
  6. Enza-A $800 1 payment
  7. EA Inserter $800 1 payment
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $62 3 payments
  9. PROCLAIM $26 1 payment
  10. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $18 1 payment
  11. Other $37 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

601

Median for Neurosurgery: 83

Drug cost

$4,392

Median for Neurosurgery: $872

Branded share of claims

19.3%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 92 $978
Gabapentin Generic 101 $970
Pregabalin Generic 41 $780
Celecoxib Generic 24 $398
Meloxicam Generic 149 $340
Oxycodone Hcl Generic 35 $251
Clindamycin Hcl Generic 42 $178
Ondansetron Odt Ondansetron Brand 24 $144
Tramadol Hcl Generic 38 $144
Baclofen Generic 23 $119

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$126,786

Of which drugs: $176

Medicare patients

126

Average age 72

Services billed

779

65 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 26%
Chronic kidney disease 24%
Depression 23%
COPD 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 242 $174
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 17 18 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record